Clearly, however, treatment with a DPP-4 inhibitor (sitagliptin or vildagliptin) reduces the incidence of hypoglycaemia relative to treatment with a sulphonylurea agent during Ramadan. This evidence concerns the gene DPP4 and Hypoglycemia.